8月5日,辉瑞公布2025H1业绩,上半年总营收283.67亿美元(+1%)。从业务板块来看,肿瘤、初级护理(Primary Care)、专科护理(Specialty Care)三大业务在今年上半年分别收入81.45亿美元(+9%)、112.36亿美元(-8%)、83.64亿美元(+6%)。扛起肿瘤业务大旗的还是乳腺癌重磅药物Ibrance(哌柏西利,CDK4/6抑制剂),尽管因为激烈的竞争其...
Source Link8月5日,辉瑞公布2025H1业绩,上半年总营收283.67亿美元(+1%)。从业务板块来看,肿瘤、初级护理(Primary Care)、专科护理(Specialty Care)三大业务在今年上半年分别收入81.45亿美元(+9%)、112.36亿美元(-8%)、83.64亿美元(+6%)。扛起肿瘤业务大旗的还是乳腺癌重磅药物Ibrance(哌柏西利,CDK4/6抑制剂),尽管因为激烈的竞争其...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.